Quarterly report [Sections 13 or 15(d)]

BUSINESS COMBINATION (Details Narrative)

v3.25.3
BUSINESS COMBINATION (Details Narrative) - USD ($)
9 Months Ended
Mar. 04, 2025
Sep. 30, 2025
Dec. 31, 2024
Oct. 14, 2024
BUSINESS COMBINATION        
Retention description amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra      
Common stock shares issued 500,000 104,500    
Common stock price per share $ 0.31 $ 0.001 $ 0.001 $ 0.75
Common stock purchase 500,000      
Exercise price $ 1.00      
Fair value of stock issued $ 153,500      
Royalty payments   $ 192,365    
Upfront purchase price $ 400,000 $ 392,441    
Discounted at the risk-free rate   4.04%    
Discounted at required metric risk premium   $ 27.78    
Acquisition-related costs   $ 219,359    
Pro forma adjusted amount   $ 219,359